Efficacy and safety of artemether+lumefantrine & dihydroartemisinin+piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in different sentinel site in Suda
Phase 4
Recruiting
- Conditions
- Malaria
- Registration Number
- ACTRN12617000276358
- Lead Sponsor
- Federal Ministry of Health
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 440
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of artemether+lumefantrine and dihydroartemisinin+piperaquine in treating Plasmodium falciparum malaria?
How do the efficacy outcomes of artemether+lumefantrine and dihydroartemisinin+piperaquine compare to standard-of-care treatments for uncomplicated P. falciparum malaria in Sudan?
Which biomarkers are associated with treatment response or resistance to artemisinin-based combination therapies (ACTs) in P. falciparum malaria patients in Sudanese sentinel sites?
What are the known or potential adverse events associated with artemether+lumefantrine and dihydroartemisinin+piperaquine in ACTRN12617000276358, and how are they managed in clinical practice?
What are the current trends in artemisinin-based combination therapies (ACTs) for P. falciparum malaria, and how does this trial contribute to the therapeutic landscape in Sudan?